✦ LIBER ✦

Review of drug development and therapeutic role of cholinesterase inhibitors in Alzheimer's disease

✍ Scribed by John J. Sramek; Victoria Zarotsky; Neal R. Cutler

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 80 KB
Volume: 56
Category: Article
ISSN: 0272-4391
DOI: 10.1002/ddr.10087

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Researchers have for some time appreciated the role of the neurotransmitter acetylcholine in Alzheimer's disease, and have realized the development of a number of acetylcholinesterase inhibitors. Bridging and dynabridging studies have played an important role in the development of these agents. Several acetylcholinesterase inhibitors have demonstrated tolerability and efficacy in a number of clinical trials. The most common adverse events associated with acetylcholinesterase inhibitors are cholinergic in nature, namely nausea and vomiting. The various properties of the three acetylcholinesterase inhibitors in clinical use today provide the clinician with the only meaningful treatment choices for Alzheimer's disease (AD) at the present time. Drug Dev. Res. 56:347–353, 2002. Copyright © 2002 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Advances in the development of kinase in

Advances in the development of kinase inhibitor therapeutics for Alzheimer's disease

✍ Mary J. Savage; Diane E. Gingrich 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 576 KB

## Abstract Pharmaceutical approaches to slow the progression of Alzheimer's disease (AD) have focused primarily on reducing production or increasing clearance of amyloid β peptide (Aβ). Recent clinical trial results question the efficacy of targeting Aβ for treatment of mild to moderate AD, highli

The role and therapeutic potential of mo

The role and therapeutic potential of monocytic cells in Alzheimer's disease

✍ Tarja Malm; Milla Koistinaho; Anu Muona; Johanna Magga; Jari Koistinaho 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 295 KB 👁 1 views

## Abstract Alzheimer's disease (AD) is a dementing neurodegenerative disorder without a cure. The abnormal parenchymal accumulation of β‐amyloid (Aβ) is associated with inflammatory reactions involving microglia and astrocytes. Increased levels of Aβ and Aβ deposition in the brain are thought to c

Role of proteoglycans and glycosaminogly

Role of proteoglycans and glycosaminoglycans in the pathogenesis of Alzheimer's disease and related disorders: Amyloidogenesis and therapeutic strategies—A review

✍ Toshio Ariga; Tadashi Miyatake; Robert K. Yu 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB

## Abstract The extracellular accumulation of amyloid β proteins (Aβs) in neuritic plaques is one of the hallmarks of Alzheimer's disease (AD). The binding of Aβs to extracellular membranes (ECMs) is a critical step in developing AD. Aβs bind to many biomolecules, including lipids, proteins, and pr

Mechanisms of Neuroprotective Effects of

Mechanisms of Neuroprotective Effects of Therapeutic Acetylcholinesterase Inhibitors Used in Treatment of Alzheimer′s Disease

✍ Yuki Takatori 📂 Article 📅 2006 🏛 John Wiley and Sons ⚖ 8 KB 👁 1 views

Role of the SNK-SPAR pathway in the deve

Role of the SNK-SPAR pathway in the development of Alzheimer's disease

✍ Xiaoyang Gong; Xiaoguang Lu; Libin Zhan; Hua Sui; Xin Qi; Zhenghong Ji; Xinping 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 663 KB

## Abstract Alzheimer's disease (AD) is characterized by the presence of senile plaques and neurofibrillary tangles in the brain. The beta‐amyloid peptide (Aβ) is the primary constituent of the senile plaques, and has been proposed to be a key contributor to the neurodegeneration observed in AD. Th

Development of a novel neuroprotective d

Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities

✍ Marta Weinstock; Tamar Goren; Moussa B. H. Youdim 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 2 views